FE65 and FE65L1 share common synaptic functions and genetically interact with the APP family in neuromuscular junction formation.

The FE65 adaptor proteins (FE65, FE65L1 and FE65L2) bind proteins that function in diverse cellular pathways and are essential for specific biological processes. Mice lacking both FE65 and FE65L1 exhibit ectopic neuronal positioning in the cortex and muscle weakness. p97FE65-KO mice, expressing a shorter FE65 isoform able to bind amyloid precursor protein family members (APP, APLP1, APLP2), develop defective long-term potentiation (LTP) and aged mice display spatial learning and memory deficits that are absent from young mice.

Adhesion maturation of neutrophils on nanoscopically presented platelet glycoprotein Ibα.

Neutrophilic granulocytes play a fundamental role in cardiovascular disease. They interact with platelet aggregates via the integrin Mac-1 and the platelet receptor glycoprotein Ibα (GPIbα). In vivo, GPIbα presentation is highly variable under different physiological and pathophysiological conditions.

Investigating cell-ECM contact changes in response to hypoosmotic stimulation of hepatocytes in vivo with DW-RICM.

Hepatocyte volume regulation has been shown to play an important role in cellular metabolism, proliferation, viability and especially in hepatic functions such as bile formation and proteolysis. Recent studies on liver explants led to the assumption that cell volume changes present a trigger for outside-in signaling via integrins, a protein family involved in mediating cellular response to binding to the extracellular matrix (ECM). However, it remains elusive how these volume change related signaling events are transducted on a single cell level and how these events are influenced and controlled by ECM interactions.

Herpes simplex virus: Drug resistance and new treatment options using natural products (Review).

As herpes simplex infections are very common worldwide, new treatment options are of high importance, especially for immunosuppressed individuals. Although the standard treatment options have shown high effectiveness for decades, the risk that drug resistance will emerge remains significant. It is therefore important that new drug targets and new treatments are investigated, not just in preliminary tests, but also in vitro, in vivo and by clinical testing.